ArticleBMC ophthalmology2026
Pars plana vitrectomy in uveitis of diverse etiologies: indications and surgical outcomes.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the indications, surgical outcomes, and diagnostic role of pars plana vitrectomy (PPV) in uveitis of diverse etiologies.
methodsThis retrospective study included 32 eyes (30 patients) undergoing 23-gauge PPV during 2019-2025. Uveitis etiology, surgical indications, and pre- and postoperative best-corrected visual acuity (BCVA) were analyzed. The primary outcome was change in BCVA, while secondary outcomes included anatomical success in retinal detachment (RD) cases, clinically meaningful visual improvement, diagnostic yield, and postoperative complications.
resultsThe most common etiologies were idiopathic uveitis (16.7%) and suspected primary vitreoretinal lymphoma (16.7%). Main surgical indications included tractional RD (28.1%), rhegmatogenous RD (21.9%), and diagnostic vitrectomy (18.8%). Final anatomical success was achieved in 93.8% of RD cases. BCVA improvement remained statistically significant at 1, 6, and 12 months after correction for multiple comparisons, while a gain of ≥ 2 Snellen lines was achieved in 46.2% of eyes at the final follow-up visit. No severe postoperative inflammation occurred.
conclusionsPPV is a safe and effective approach for managing vitreoretinal complications and diagnostic evaluation in uveitis, with favorable anatomical and functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.